WO2017146443A1 - 폴리에틸렌글리콜 디알데히드 유도체의 제조방법 - Google Patents
폴리에틸렌글리콜 디알데히드 유도체의 제조방법 Download PDFInfo
- Publication number
- WO2017146443A1 WO2017146443A1 PCT/KR2017/001906 KR2017001906W WO2017146443A1 WO 2017146443 A1 WO2017146443 A1 WO 2017146443A1 KR 2017001906 W KR2017001906 W KR 2017001906W WO 2017146443 A1 WO2017146443 A1 WO 2017146443A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peg
- formula
- dialdehyde
- compound
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3312—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
- C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
- C08G65/3346—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur having sulfur bound to carbon and oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/07—Aldehydes; Ketones
Definitions
- the present invention is directed to an improved process for preparing high purity polyethylene glycol dialdehyde derivatives.
- PEG Polyethylene glycol
- PEG derivatives in which various functional groups are introduced into the hydroxyl group (OH group) at the PEG chain end are used.
- PEG derivatives include PEG-aldehyde, PEG-acetaldehyde, PEG-propionaldehyde, and the like.
- the aldehyde group present at the terminal of the derivative can selectively react with the amino terminal of the protein.
- U. S. Patent No. 6,465, 694 discloses a process of oxidizing a PEG-terminated hydroxy group to an aldehyde group by reacting PEG with oxygen under a catalyst.
- a method using the oxidation reaction has a problem that can degrade the PEG chain.
- an acetal group to the PEG terminal to prepare an aldehyde group through a hydrolysis reaction and an oxidation reaction it is difficult to commercialize because the raw materials used are expensive.
- US Pat. No. 5,252,714 discloses a process for preparing PEG-propionaldehyde by reacting PEG with 3-chlorodiethylacetalpropion-aldehyde and then hydrolyzing under acidic conditions.
- U.S. Patent No. 4,002,531 discloses a PEGylation reaction (PEGylation or pegylation) to introduce PEG into the drug, by oxidizing mPEG (methoxy-PEG) to prepare mPEG-acetaldehyde, using the trypsin enzyme PEGylation reaction is used in drug delivery system.
- PEGylation reaction PEGylation or pegylation
- mPEG methoxy-PEG
- trypsin enzyme PEGylation reaction is used in drug delivery system.
- this oxidation reaction may decompose PEG chains to increase the distribution, and the reaction conversion rate may be lowered to 80% or less.
- the present inventors have studied the method for preparing polyethylene glycol dialdehyde derivatives more safely and efficiently, and found that PEG-diacetal can be used as an intermediate to prepare polyethylene glycol dialdehyde derivatives of high purity. Was completed.
- R 1 and R 2 are the same as or different from each other, each independently represent a (C1-C9) alkyl group, and n is an integer from 3 to 2000.
- the preparation method according to the present invention is suitable for mass production because of no separation process (purification process), such as column chromatography, and the polyethylene glycol dialdehyde derivative suitable as a raw material for pharmaceuticals due to its high purity and terminal activity.
- purification process such as column chromatography
- polyethylene glycol dialdehyde derivative suitable as a raw material for pharmaceuticals due to its high purity and terminal activity.
- 'PEG-dialdehyde' Method for producing a polyethylene glycol dialdehyde derivative (hereinafter referred to as 'PEG-dialdehyde') of the present invention, (1) to activate the compound of the formula (2) in the presence of a metal base in a solvent and PEGylated with a compound of the formula (1) Reacting to prepare a compound of Formula 3; And (2) reacting the compound of Formula 3 with an acid in a solvent to prepare a compound of Formula 4.
- step (1) by activating the compound of Formula 2 (dialkoxy-1-propanol) and PEGylation with the compound of Formula 1 (PEG-Ms) (PEGylation) To prepare a compound (PEG-diacetal).
- R 1 and R 2 are the same as or different from each other, each independently represent a (C1-C9) alkyl group, and n is an integer from 3 to 2000.
- the alkyl group of R 1 and R 2 is a linear or branched alkyl group, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, hexyl, heptyl, octyl, or nonyl, Preferably C1-C4, more preferably methyl, ethyl, propyl, isopropyl or butyl, most preferably ethyl.
- N is directly related to the molecular weight of the polyethylene glycol (PEG) to be produced finally, it may be an integer of 3 to 2000.
- step (1) the compound of Formula 2 (dialkoxy-1-propanol) is added to a solvent in an inert gas atmosphere or in an inert atmosphere in which inert gas is continuously introduced, followed by stirring to activate the metal base.
- the compound of formula 1 (PEG-Ms) by PEGylation reaction may be prepared in the solution of the compound of formula (3) (PEG-diacetal).
- the reaction of step (1) may be carried out under (i) an inert gas atmosphere in which the gas inside the reactor is replaced with an inert gas, or (ii) the inert gas is continuously introduced to continuously replace the gas in the reactor.
- an inert gas atmosphere in which the gas inside the reactor is replaced with an inert gas
- the inert gas is continuously introduced to continuously replace the gas in the reactor.
- the flow rate of the inert gas may be 0.1 to 6.0 L / min, specifically 0.5 to 4.0 L / min, more specifically 0.5 to 2.0 L / min.
- the inert gas may be at least one selected from the group consisting of nitrogen, argon and helium, and preferably nitrogen.
- the solvent used in the reaction of step (1) may be at least one selected from the group consisting of toluene, dichloromethane, chloroform, tetrahydrofuran, acetonitrile and 1,4-dioxane.
- the metal base may be a metal alkoxide, metal hydride or a mixture thereof.
- the metal alkoxide may be at least one selected from the group consisting of sodium methoxide, sodium ethoxide, sodium t-butoxide, sodium t-pentoxide, potassium t-butoxide and potassium t-pentoxide.
- the metal hydride may be sodium hydride.
- the metal base may be used in an amount of 1 to 10 equivalents, preferably 3 to 7 equivalents, based on 1 equivalent of the compound of Formula 1 (PEG-Ms).
- dialkoxy-1-propanol examples include dimethoxy-1-propanol, diethoxy-1-propanol, dipropoxy-1-propanol, dibutoxy-1-propanol, and diisopropoxy -1-propanol etc. are mentioned.
- the compound of Formula 2 may be used in an amount of 2 to 30 equivalents based on 1 equivalent of the compound of Formula 1, preferably in an amount of 5 to 15 equivalents.
- step (1) The activation treatment of step (1) may be carried out at a temperature condition of 20 °C to 90 °C, preferably may be carried out at 35 °C to 80 °C.
- the PEGylation reaction (PEGylation) of step (1) may be carried out at a temperature condition of 0 °C to 90 °C, preferably may be carried out at 0 °C to 40 °C.
- the activation treatment and PEGylation reaction of this step (1) directly affect the terminal activity of PEG-dialdehyde.
- the term 'terminal activity' means that an aldehyde group, which is a functional group having activity at the terminal of PEG-dialdehyde, is present.
- the higher the value of the terminal activity means that the content of the dialdehyde present in the PEG terminal, the higher the terminal activity is 100% means that 100% of the CHO is bonded to both ends of the PEG.
- the aldehyde group may selectively react with the amino terminus of the protein or peptide.
- the term 'terminal activity' may be interpreted as the degree of PEGylation that can be introduced into PEG-dialdehyde. Therefore, in order to use as a raw material of a drug such as a bio drug (bio drug), it is advantageous that the aldehyde group is present at both ends of the PEG-dialdehyde in a high proportion.
- step (2) of the present invention described later is relatively quick and easy and can be reacted at a high conversion rate, step (1) is important to secure high terminal activity.
- the PEG of Chemical Formula 1 reacts with the compound of Chemical Formula 2, and at this time, the reaction parameter is adjusted during activation of the hydroxyl group of the Chemical Formula 2 to increase the reactivity between the Chemical Formula 1 and Chemical Formula 2 Prepare the compound.
- any one or more of those described above may be used as the metal base, and sodium t-pentoxide is preferably used.
- the inert gas is introduced at the above-described flow rate, PEG-dialdehyde having improved terminal activity can be obtained.
- the subsequent treatment process may be considered with regard to terminal activity.
- the compound of formula 3 (PEG-diacetal) prepared after the PEGylation reaction in step (1) may be isolated for crystallization into a solid phase or concentrated in an oil phase to be used in the next step, or alternatively It can be prepared in solution by the reaction of (1) and then used in-situ for the reaction of the subsequent step (2) without separation. That is, in the case of (ii), the reaction solution obtained in step (1) can be used continuously ( in-situ ) in the reaction of step (2) without separation.
- the terminal activity is further improved when the compound of Formula 3 is applied to the next step in the continuous use manner.
- step (2) as shown in Scheme 2, the compound of formula (3) prepared in step (1) (PEG-diacetal) is reacted with an acid in a solvent to the compound of formula (4) (PEG-dialdehyde) Manufacture.
- step (2) the compound of formula (3) (PEG-diacetal) obtained in solution by the reaction of step (1) was added to an aqueous acid solution in a solvent, followed by reaction
- the mixture of Chemical Formula 4 (PEG-dialdehyde) may be prepared by treating with a solvent.
- the solvent used in the reaction of step (2) may be selected from the group consisting of water, methanol, ethanol, propanol, t-butanol and mixtures thereof.
- the solvent used in the reaction of step (2) may comprise water.
- the acid may also be selected from the group consisting of hydrochloric acid, acetic acid, formic acid, trifluoroacetic acid, phosphoric acid and mixtures thereof.
- step (2) may be carried out at a temperature condition of 0 °C to 50 °C, preferably may be carried out at 20 °C to 30 °C.
- the solution obtained through the reaction of step (2) may be further subjected to extraction, concentration, crystallization, etc. using an organic solvent.
- the organic solvent may be selected from the group consisting of dichloromethane, chloroform, ethyl acetate and mixtures thereof.
- the organic solvent used for the extraction may be selected from the group consisting of dichloromethane, chloroform, ethyl acetate and mixtures thereof.
- the organic solvent used for the crystallization includes (a) at least one solvent selected from the group consisting of dichloromethane, chloroform and ethyl acetate, and (b) hexane, heptane, diethyl ether and methyl t-butyl ether.
- One or more solvents selected from the group can be used in combination.
- the formula (2) and R 1 and R 2 are the same of the compound of formula 3, which may be an acetate.
- the reaction of step (1) may be performed under an inert gas atmosphere or in a state in which inert gas is continuously introduced.
- the inert gas may be selected from the group consisting of nitrogen, argon, helium and mixtures thereof.
- the compound of Formula 3 may be prepared in solution by the reaction of step (1) and then used in-situ for the reaction of step (2) without separation.
- the acid used in step (2) may be hydrochloric acid.
- the compound of Formula 4 may be obtained by treating the solution obtained by the reaction of step (2) with an organic solvent.
- the organic solvent may include one or more selected from the group consisting of dichloromethane, chloroform and ethyl acetate.
- step (1) of the present invention can be prepared by the route shown in Scheme 3.
- the compound of Formula 1 may be prepared by reacting polyethylene glycol (PEG) and methanesulfonyl chloride (MsCl) in the presence of a base.
- PEG polyethylene glycol
- MsCl methanesulfonyl chloride
- the base used in the preparation of the compound of Formula 1 may be triethylamine, tributylamine, or a mixture thereof.
- PEG-dialdehyde having high purity can be stably and reproducibly produced by reacting a compound in which methanesulfonyl chloride is introduced into a leaving group into PEG as a starting material as a starting material.
- the manufacturing method of the present invention preferably does not include performing the column chromatography, and thus is suitable for mass production, and efficiently and reproducibly produces a high quality product. There is an advantage to produce.
- the purity and terminal activity is high, there is an advantage that can provide a polyethylene glycol dialdehyde derivative suitable as a raw material of pharmaceutical products.
- the polyethylene glycol dialdehyde derivative prepared according to the present invention exhibits terminal activity of 60% or more, preferably 70% or more, more preferably 80% or more.
- Mn Number average molecular weight
- PDI polydispersity index
- MPF main peak fraction
- Terminal activity It was analyzed by a RI index (refractive index detector) through an ion exchange column using high performance liquid chromatography (HPLC).
- Nitrogen gas was continuously introduced into the reaction vessel, and the reaction vessel was flame dried to remove moisture.
- 100 g of PEG (Mn about 3.4 K) was added to the reaction vessel, and 300 mL of dichloromethane was added thereto to dissolve and cooled to 5 ° C. 23.0 mL of triethylamine was added to the reaction solution, and 12.6 mL of methanesulfonyl chloride was added at 5 ° C.
- the reaction solution was stirred at 5 ° C. for 2.5 hours, 300 mL of distilled water was added thereto, followed by stirring for 10 minutes to separate an organic layer.
- 300 mL of dichloromethane was added to the aqueous layer, followed by further extraction. The organic layers were separated and combined.
- Nitrogen gas was continuously introduced into two 500 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Nitrogen gas was continuously introduced into two 500 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Terminal activity 73.1%.
- Nitrogen gas was continuously introduced into two 500 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Terminal activity 77.1%.
- Nitrogen gas was continuously introduced into two 500 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Nitrogen gas was continuously introduced into two 500 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Nitrogen gas was continuously introduced into two 500 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Terminal activity 81.4%.
- Example 6 The same procedure as in Example 6 was repeated except that 0.98 g of sodium ethoxide was used as the metal base, to obtain 3.67 g (37% yield) of PEG-dialdehyde.
- Example 6 The same procedure as in Example 6 was repeated except that 1.38 g of sodium t-butoxide was used as the metal base, to obtain 2.98 g (yield: 30%) of PEG-dialdehyde.
- Example 6 The same procedure as in Example 6 was repeated except that 1.58 g of sodium t-pentoxide was used as the metal base, and 4.68 g (yield: 48%) of PEG-dialdehyde was obtained.
- Example 6 The same procedure as in Example 6 was repeated except that 0.58 g of 60% sodium hydride was used as the metal base, to obtain 4.36 g (44%) of PEG-dialdehyde.
- Terminal activity 81.9%.
- Nitrogen gas was continuously introduced into two 250 mL reaction vessels, and the reaction vessels were flame dried to remove moisture.
- Terminal activity 82.1%.
- Terminal activity 81.4%.
- Terminal activity 83.1%.
- Example 5 The same procedure as in Example 5 was repeated except that helium gas was used instead of nitrogen gas as an inert gas, to obtain 4.3 g (yield: 44%) of PEG-dialdehyde.
- Terminal activity 69.5%.
- Terminal activity 68.0%.
- Nitrogen gas was continuously introduced into the two reaction vessels, and the reaction vessels were flame dried to remove moisture.
- the present invention is carried out in an inert atmosphere upon activation, and the following table 1 compares the terminal activity of the PEG-dialdehyde finally obtained for the inactivation of the inert atmosphere.
- Example 6 Comparative Example 1 Sodium methoxide 81.4 13.0
- Example 7 Comparative Example 2
- Example 8 Comparative Example 3
- Example 9 Comparative Example 4
- Example 10 Comparative Example 5
- Example 11 Comparative Example 6
- Example 12 Comparative Example 7
- the PEG-dialdehyde can be produced with excellent terminal activity only when performed under nitrogen atmosphere during activation.
- Table 2 compares the yield and terminal activity according to the type of gas in an inert atmosphere.
- Table 3 compares the yield and terminal activity according to the flow rate of the inert gas.
- Example 1 Potassium t-butoxide Extraction-concentration-crystallization 66.8
- Example 2 Potassium t-butoxide Extraction-concentration 73.1
- Example 3 Potassium t-butoxide Extraction (used as in-situ ) 77.1
- Example 4 Sodium t-pentoxide Extraction (used as in-situ ) 82.6
- Example 5 Sodium t-pentoxide Extraction (used as in-situ ) 85.8
- the terminal activity of the PEG-dialdehyde finally obtained according to the separation and purification process of PEG-diethylacetal after the PEGylation reaction is lowered when crystallization is performed, and when the separated solution is used in the next step after performing the extraction process by the organic layer ( in-situ ), the PEG-dialdehyde has excellent terminal activity. It can be seen that manufacturing is possible.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyethers (AREA)
Abstract
Description
구분 | 금속 염기 | 말단 활성 (%) | |
질소 사용 (실시예) | 질소 미사용 (비교예) | ||
실시예 6 / 비교예 1 | 소듐 메톡사이드 | 81.4 | 13.0 |
실시예 7 / 비교예 2 | 소듐 에톡사이드 | 77.8 | 33.6 |
실시예 8 / 비교예 3 | 소듐 t-부톡사이드 | 81.7 | 33.9 |
실시예 9 / 비교예 4 | 포타슘 t-부톡사이드 | 81.7 | 69.5 |
실시예 10 / 비교예 5 | 소듐 t-펜톡사이드 | 85.8 | 49.1 |
실시예 11 / 비교예 6 | 포타슘 t-펜톡사이드 | 82.3 | 69.8 |
실시예 12 / 비교예 7 | 소듐 하이드라이드 | 81.9 | 68.0 |
구분 | 비활성 기체 | 수율(%) | 말단 활성(%) |
실시예 5 | 질소 | 48 | 85.8 |
실시예 17 | 아르곤 | 47 | 83.1 |
실시예 18 | 헬륨 | 44 | 82.4 |
비교예 5 | X | 29 | 49.1 |
구분 | N2 유량(L/min) | 활성화 후 남은용액량 ( mL) | 수율(%) | 말단 활성(%) |
비교예 9 | 0 | 23 | 30 | 50.1 |
실시예 13 | 0.56 | 23 | 36 | 83.7 |
실시예 14 | 1.1 | 15 | 39 | 86.4 |
실시예 15 | 2.8 | 7 | 38 | 82.1 |
실시예 16 | 3.7 | 2 | 41 | 81.4 |
구분 | 금속 염기 | 분리 정제 방식 | 말단 활성(%) |
실시예 1 | 포타듐 t-부톡사이드 | 추출-농축-결정화 | 66.8 |
실시예 2 | 포타듐 t-부톡사이드 | 추출-농축 | 73.1 |
실시예 3 | 포타듐 t-부톡사이드 | 추출 (in-situ로 사용) | 77.1 |
실시예 4 | 소듐 t-펜톡사이드 | 추출 (in-situ로 사용) | 82.6 |
실시예 5 | 소듐 t-펜톡사이드 | 추출 (in-situ로 사용) | 85.8 |
Claims (15)
- 제1항에 있어서,상기 금속 염기는 금속 알콕사이드 및 금속 하이드라이드로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는 방법.
- 제2항에 있어서,상기 금속 알콕사이드는 소듐 메톡사이드, 소듐 에톡사이드, 소듐 t-부톡사이드, 소듐 t-펜톡사이드, 포타슘 t-부톡사이드 및 포타슘 t-펜톡사이드로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는 방법.
- 제2항에 있어서,상기 금속 하이드라이드는 소듐 하이드라이드인 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 활성화 처리는 20℃ 내지 90℃에서 수행하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 페길화 반응은 0℃ 내지 90℃에서 수행하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 (1)은 비활성 기체 대기 하에서 또는 비활성 기체가 지속적으로 유입되는 비활성 분위기에서 수행되는 것을 특징으로 하는 방법.
- 제7항에 있어서,상기 비활성 분위기는 질소, 아르곤 및 헬륨으로 이루어진 군으로부터 선택된 1종 이상의 비활성 기체를 유입시켜 형성하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 (1)은 톨루엔, 디클로로메탄, 클로로포름, 테트라히드로퓨란, 아세토니트릴 및 1,4-디옥산으로 이루어진 군으로부터 선택된 1종 이상의 용매 하에 수행하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 (1)에서 제조된 화학식 3의 화합물은 그대로 단계 (2)에 연속적으로(in-situ) 적용하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 (2)의 산 처리는 염산, 아세트산, 포름산, 트리플루오로아세트산 및 인산으로 이루어진 군으로부터 선택된 1종 이상의 산을 이용하여 수행하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 (2)의 산 처리는 0℃ 내지 50℃에서 수행하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 (2)는 물, 메탄올, 에탄올, 프로판올 및 t-부탄올로 이루어진 군으로부터 선택된 1종 이상의 용매 하에 수행하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 화학식 1의 화합물은 염기 존재 하에서 폴리에틸렌글리콜(PEG)과 메탄설포닐할라이드(할라이드=Cl, Br, 또는 F)를 반응시켜 제조된 것을 특징으로 하는 방법.
- 제14항에 있어서,상기 염기는 트리에틸아민 및 트리부틸아민으로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17756781.5A EP3421521B1 (en) | 2016-02-26 | 2017-02-21 | Method for preparing polyethylene glycol dialdehyde derivative |
MX2018009847A MX2018009847A (es) | 2016-02-26 | 2017-02-21 | Metodo para preparar derivado de polietilenglicol-dialdehido. |
BR112018067996A BR112018067996A2 (pt) | 2016-02-26 | 2017-02-21 | método para preparar um derivado de polietileno glicol dialdeído |
CN201780012402.5A CN108699236B (zh) | 2016-02-26 | 2017-02-21 | 聚乙二醇二醛衍生物的制备方法 |
JP2018545151A JP6927990B2 (ja) | 2016-02-26 | 2017-02-21 | ポリエチレングリコールジアルデヒド誘導体の製造方法 |
US16/074,592 US10781285B2 (en) | 2016-02-26 | 2017-02-21 | Method for preparing polyethylene glycol dialdehyde derivative |
AU2017224389A AU2017224389A1 (en) | 2016-02-26 | 2017-02-21 | Method for preparing polyethylene glycol dialdehyde derivative |
CA3013750A CA3013750A1 (en) | 2016-02-26 | 2017-02-21 | Method for preparing polyethylene glycol dialdehyde derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160023217A KR102247701B1 (ko) | 2016-02-26 | 2016-02-26 | 폴리에틸렌글리콜 디알데히드 유도체의 제조방법 |
KR10-2016-0023217 | 2016-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017146443A1 true WO2017146443A1 (ko) | 2017-08-31 |
Family
ID=59686442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/001906 WO2017146443A1 (ko) | 2016-02-26 | 2017-02-21 | 폴리에틸렌글리콜 디알데히드 유도체의 제조방법 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10781285B2 (ko) |
EP (1) | EP3421521B1 (ko) |
JP (1) | JP6927990B2 (ko) |
KR (1) | KR102247701B1 (ko) |
CN (1) | CN108699236B (ko) |
AU (1) | AU2017224389A1 (ko) |
BR (1) | BR112018067996A2 (ko) |
CA (1) | CA3013750A1 (ko) |
MX (1) | MX2018009847A (ko) |
WO (1) | WO2017146443A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021010532A1 (ko) * | 2019-07-18 | 2021-01-21 | 한미약품 주식회사 | 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법 |
WO2021010531A1 (ko) * | 2019-07-18 | 2021-01-21 | 한미약품 주식회사 | 단백질 결합체의 신규 제조 방법 |
WO2024041225A1 (zh) * | 2022-08-26 | 2024-02-29 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇醛衍生物的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220036720A (ko) * | 2020-09-16 | 2022-03-23 | 한미정밀화학주식회사 | 폴리에틸렌글리콜 유도체, 이를 포함하는 조성물 및 이를 이용한 생리활성 폴리펩타이드 결합체의 제조 방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US6465694B1 (en) * | 1998-10-26 | 2002-10-15 | University Of Utah Research Foundation | Method for preparation of polyethylene glycol aldehyde derivatives |
US20070167606A1 (en) * | 2002-07-24 | 2007-07-19 | Chee-Youb Won | Polyethylene glycol aldehydes |
KR100967833B1 (ko) * | 2008-05-20 | 2010-07-05 | 아이디비켐(주) | 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법 |
US20120077988A1 (en) * | 2010-06-25 | 2012-03-29 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
WO2001026692A1 (en) | 1999-10-08 | 2001-04-19 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US8828373B2 (en) * | 2002-11-20 | 2014-09-09 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
JP5515224B2 (ja) * | 2007-02-28 | 2014-06-11 | 日油株式会社 | 多分岐鎖ポリオキシアルキレン誘導体 |
JP5825507B2 (ja) | 2010-06-25 | 2015-12-02 | 日油株式会社 | 分岐型ヘテロポリエチレングリコール |
JP6051998B2 (ja) | 2012-03-30 | 2016-12-27 | 日油株式会社 | マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法 |
JP5798100B2 (ja) * | 2012-10-16 | 2015-10-21 | 信越化学工業株式会社 | レジスト材料及びこれを用いたパターン形成方法 |
CN103834002B (zh) * | 2014-02-18 | 2016-02-17 | 苏州大学 | 基于聚乙二醇的酸敏感性阿霉素前药及其制备方法与应用 |
-
2016
- 2016-02-26 KR KR1020160023217A patent/KR102247701B1/ko active IP Right Grant
-
2017
- 2017-02-21 CA CA3013750A patent/CA3013750A1/en not_active Abandoned
- 2017-02-21 JP JP2018545151A patent/JP6927990B2/ja active Active
- 2017-02-21 AU AU2017224389A patent/AU2017224389A1/en not_active Abandoned
- 2017-02-21 US US16/074,592 patent/US10781285B2/en active Active
- 2017-02-21 BR BR112018067996A patent/BR112018067996A2/pt not_active Application Discontinuation
- 2017-02-21 EP EP17756781.5A patent/EP3421521B1/en active Active
- 2017-02-21 WO PCT/KR2017/001906 patent/WO2017146443A1/ko active Application Filing
- 2017-02-21 CN CN201780012402.5A patent/CN108699236B/zh active Active
- 2017-02-21 MX MX2018009847A patent/MX2018009847A/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US6465694B1 (en) * | 1998-10-26 | 2002-10-15 | University Of Utah Research Foundation | Method for preparation of polyethylene glycol aldehyde derivatives |
US20070167606A1 (en) * | 2002-07-24 | 2007-07-19 | Chee-Youb Won | Polyethylene glycol aldehydes |
KR100967833B1 (ko) * | 2008-05-20 | 2010-07-05 | 아이디비켐(주) | 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법 |
US20120077988A1 (en) * | 2010-06-25 | 2012-03-29 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
Non-Patent Citations (1)
Title |
---|
See also references of EP3421521A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021010532A1 (ko) * | 2019-07-18 | 2021-01-21 | 한미약품 주식회사 | 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법 |
WO2021010531A1 (ko) * | 2019-07-18 | 2021-01-21 | 한미약품 주식회사 | 단백질 결합체의 신규 제조 방법 |
US11717577B2 (en) | 2019-07-18 | 2023-08-08 | Hanmi Pharm. Co., Ltd. | Method for preparing long-acting drug conjugate through preparation of intermediate |
WO2024041225A1 (zh) * | 2022-08-26 | 2024-02-29 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇醛衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6927990B2 (ja) | 2021-09-01 |
KR102247701B1 (ko) | 2021-05-03 |
US20190040196A1 (en) | 2019-02-07 |
CN108699236B (zh) | 2021-01-22 |
EP3421521A4 (en) | 2019-03-06 |
KR20170100842A (ko) | 2017-09-05 |
CA3013750A1 (en) | 2017-08-31 |
US10781285B2 (en) | 2020-09-22 |
EP3421521A1 (en) | 2019-01-02 |
MX2018009847A (es) | 2018-11-09 |
BR112018067996A2 (pt) | 2019-01-15 |
AU2017224389A1 (en) | 2018-10-04 |
JP2019507819A (ja) | 2019-03-22 |
CN108699236A (zh) | 2018-10-23 |
EP3421521B1 (en) | 2020-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017146443A1 (ko) | 폴리에틸렌글리콜 디알데히드 유도체의 제조방법 | |
WO2020145513A1 (ko) | L-글루포시네이트 중간체 및 l-글루포시네이트 제조 방법 | |
EP2588474A2 (en) | Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof | |
AU2020412716A1 (en) | Methods of preparing N6-((2-azidoethoxy)carbonyl)lysine | |
WO2018066872A1 (ko) | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체 및 이의 광학 이성질체 합성 방법 | |
WO2022265240A1 (ko) | 트리사이클로데칸 디메탄올 조성물 및 이의 제조방법 | |
WO2023121379A1 (ko) | 에틸렌-비닐알코올 공중합체의 제조 방법 | |
WO2017191914A2 (ko) | 아미노실란계 화합물의 신규 제조방법 | |
WO2012153991A2 (ko) | 스트레커 반응용 촉매를 사용하는 키랄성 α-아미노나이트릴의 제조방법 | |
WO2021194244A1 (ko) | 신규한 이노토디올의 제조방법 | |
WO2020036382A1 (ko) | Sglt 저해제의 합성에 유용한 중간체의 제조 | |
WO2022146093A1 (ko) | 이소시아네이트 화합물의 제조 방법 | |
WO2022119070A1 (ko) | 카보네이트 유도체 제조용 셀레늄계 촉매 시스템 및 그를 이용한 카보네이트 유도체의 제조방법 | |
WO2019088800A2 (ko) | 폴리에틸렌글리콜 유도체 및 이의 제조방법 | |
WO2021225233A1 (ko) | 혈관 누출 차단제 화합물의 신규 결정형 | |
WO2022250347A1 (ko) | 유기 황 화합물의 제조방법 | |
WO2021101003A1 (ko) | 연속반응 공정에서의 메탄술포닐화 중간체를 이용한 글리플로진 합성 방법 | |
WO2016108319A1 (ko) | 신규 레바미피드 전구체의 염 및 이의 용도 | |
WO2022025575A1 (ko) | 퍼플루오로디알킬에테르의 제조 방법 및 퍼플루오로디알킬에테르의 제조 장치 | |
WO2019022461A1 (ko) | 화합물 및 이의 제조방법 | |
WO2022220613A1 (ko) | 스핑고신-1-인산 수용체 효능제의 신규한 제조방법 | |
WO2023128525A1 (en) | Method for preparation of benzimidazole derivatives | |
WO2023224240A1 (ko) | 사슬 말단에 설포닐 아자이드기 또는 설포닐 플루오라이드기를 포함하는 고분자 화합물 및 이의 제조 방법 | |
WO2016200210A1 (ko) | 선별적 용해도를 갖는 트리페닐메탄 유도체 및 그의 용도 | |
WO2013180415A1 (ko) | 신규한 포타슘 오가노-1h-1,2,3-트리아졸-4-일트리플루오로보레이트 유도체 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 3013750 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/009847 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2018545151 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017756781 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017756781 Country of ref document: EP Effective date: 20180926 |
|
ENP | Entry into the national phase |
Ref document number: 2017224389 Country of ref document: AU Date of ref document: 20170221 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018067996 Country of ref document: BR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17756781 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112018067996 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180906 |